An update from InspireMD ( (NSPR) ) is now available.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InspireMD, Inc. announced on October 7, 2024, the FDA approval to begin the CGUARDIANS II pivotal study for their CGuard Prime 80cm Carotid Stent System. This milestone is a significant step for the company, aiming to enhance stroke prevention and carotid disease management. The study, led by esteemed vascular surgeons Dr. Patrick Geraghty and Dr. Patrick Muck, will evaluate the device’s use during transcarotid revascularization procedures. This approval propels InspireMD towards its goal of market leadership in the U.S. and global expansion, while concurrently developing their next-generation TCAR Neuroprotection System, SwitchGuard NPS.
For detailed information about NSPR stock, go to TipRanks’ Stock Analysis page.